Literature DB >> 20429622

Dual inhibition of topoisomerases enhances apoptosis in melanoma cells.

K Rudolf1, M Cervinka, E Rudolf.   

Abstract

The cytotoxicity of topoisomerase I inhibiting camptothecin, topoisomerase II inhibiting etoposide and their combination were investigated in wild type p53 Bowes and mutant p53 SK-MEL-28 melanoma cell lines during 24h. A combination of camptothecin and etoposide (1 microg/ml + 10 microg/ml) proved to be efficient in both types of cell lines, although mutant p53 cells exhibited a higher resistance. Further studies proved that in Bowes cells, a combination of drugs induced p53-dependent mitochondrial apoptosis characterized by activation of caspases-8 and -2, -9 and -3 with some concurrent involvement of oxidative stress. In SK-MEL-28 cells, apoptosis was found to be mediated via increased oxidative stress, activation of stress kinases such as p38 and SAPK/JNK and mitochondrial dysfunction without significant involvement of p53 and its transactivated target genes. These results demonstrate efficiency of dual inhibition of topoisomerases in melanoma cells with functional as well as mutant p53 and point out at possible further investigation of this modality in preclinical and clinical oncology.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20429622     DOI: 10.4149/neo_2010_04_316

Source DB:  PubMed          Journal:  Neoplasma        ISSN: 0028-2685            Impact factor:   2.575


  3 in total

1.  Suppression of dendritic cell maturation and T cell proliferation by synovial fluid myeloid cells from mice with autoimmune arthritis.

Authors:  Colt Egelston; Júlia Kurkó; Timea Besenyei; Beata Tryniszewska; Tibor A Rauch; Tibor T Glant; Katalin Mikecz
Journal:  Arthritis Rheum       Date:  2012-10

Review 2.  Chemotherapy Resistance Mechanisms in Advanced Skin Cancer.

Authors:  Bhuvanesh Sukhlal Kalal; Dinesh Upadhya; Vinitha Ramanath Pai
Journal:  Oncol Rev       Date:  2017-03-24

3.  Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations.

Authors:  Thomas T DeLeon; Daniel R Almquist; Benjamin R Kipp; Blake T Langlais; Aaron Mangold; Jennifer L Winters; Heidi E Kosiorek; Richard W Joseph; Roxana S Dronca; Matthew S Block; Robert R McWilliams; Lisa A Kottschade; Kandelaria M Rumilla; Jesse S Voss; Mahesh Seetharam; Aleksandar Sekulic; Svetomir N Markovic; Alan H Bryce
Journal:  PLoS One       Date:  2020-03-20       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.